KRAS and lung adenocarcinoma: Ye and colleagues (24) reported a case of a patient with multiple primary lung adenocarcinoma in whom two tumors, one with EGFR mutation and one with KRAS mutation, were identified by genetic testing, and the lesion with the KRAS mutation was resected and followed by gefitinib-targeted therapy, after which the remaining lesion disappeared.